Raymond James Financial Inc. Grows Stock Holdings in TransMedics Group, Inc. $TMDX

Key Points

• Raymond James Financial Inc. increased its stake in TransMedics Group, Inc. by 135.8%, owning 145,393 shares valued at approximately $9.78 million as of the latest quarter.
• TransMedics Group reported $0.92 earnings per share for the last quarter, exceeding analysts' expectations by $0.44, alongside a revenue increase of 37.7% year-over-year.
• Institutional ownership stands at an impressive 99.67% of the company's stock, indicating strong support from institutional investors.

Raymond James Financial Inc. boosted its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 135.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 145,393 shares of the company's stock after buying an additional 83,722 shares during the quarter. Raymond James Financial Inc. owned approximately 0.43% of TransMedics Group worth $9,782,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the company. Braidwell LP purchased a new position in TransMedics Group during the fourth quarter valued at approximately $57,493,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in TransMedics Group by 16.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company's stock valued at $56,307,000 after purchasing an additional 128,474 shares in the last quarter. Mackenzie Financial Corp lifted its holdings in TransMedics Group by 73.0% during the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock valued at $51,635,000 after purchasing an additional 349,403 shares in the last quarter. Emerald Advisers LLC lifted its holdings in TransMedics Group by 22.4% during the first quarter. Emerald Advisers LLC now owns 454,794 shares of the company's stock valued at $30,599,000 after purchasing an additional 83,083 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in TransMedics Group by 12.7% during the fourth quarter. Northern Trust Corp now owns 354,622 shares of the company's stock valued at $22,111,000 after purchasing an additional 40,093 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Analyst Ratings Changes

Several brokerages have weighed in on TMDX. Morgan Stanley lifted their price target on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. Stifel Nicolaus began coverage on shares of TransMedics Group in a report on Thursday. They set a "hold" rating and a $115.00 price target on the stock. Piper Sandler reaffirmed an "overweight" rating and set a $145.00 price target (up previously from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Canaccord Genuity Group boosted their target price on shares of TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a report on Tuesday, July 15th. Finally, Oppenheimer boosted their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, TransMedics Group currently has an average rating of "Moderate Buy" and a consensus target price of $122.11.

TransMedics Group Price Performance

Shares of TMDX stock traded down $0.04 during mid-day trading on Friday, hitting $104.01. The company had a trading volume of 996,736 shares, compared to its average volume of 877,429. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $169.29. The stock's 50 day moving average price is $118.07 and its 200-day moving average price is $104.09. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17. The company has a market capitalization of $3.55 billion, a P/E ratio of 53.89 and a beta of 2.18.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.48 by $0.44. The firm had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company's quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. Equities research analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Transactions at TransMedics Group

In related news, insider Anil P. Ranganath sold 686 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the sale, the insider owned 13,955 shares of the company's stock, valued at $1,950,909. This represents a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 7.00% of the stock is currently owned by insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.